Sagimet Biosciences details 2026 meeting votes, director exit
Sagimet Biosciences Inc. reported a Board change and the results of its 2026 Annual Meeting of Stockholders.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Sagimet Biosciences Inc. reported a Board change and the results of its 2026 Annual Meeting of Stockholders. Director Tim Walbert resigned from the Board effective June 12, 2026, citing other commitments and no disagreements with the company.
At the virtual annual meeting, held June 12, 2026, with 32,017,613 Series A common shares outstanding as of the April 17, 2026 record date, stockholders elected Class III directors Jennifer Jarrett, Anne Phillips, M.D., David Happel and George Kemble, Ph.D. to serve until the 2029 annual meeting, and ratified KPMG LLP as independent registered public accounting firm for the 2026 fiscal year.
8-K Event Classification
2 items: 5.02, 5.07
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares outstanding at record date: 32,017,613 shares
Votes for KPMG ratification: 19,091,619 votes
Votes against KPMG ratification: 13,960 votes
+3 more
6 metrics
Shares outstanding at record date
32,017,613 shares
Series A common stock as of April 17, 2026 record date
Votes for KPMG ratification
19,091,619 votes
For ratification of KPMG LLP as 2026 auditor
Votes against KPMG ratification
13,960 votes
Against ratification of KPMG LLP as 2026 auditor
Abstentions on KPMG ratification
35,224 votes
Abstentions on auditor ratification proposal
Votes for David Happel
8,753,884 votes
For election as Class III director
Votes withheld for David Happel
262,813 votes
Withheld on Class III director election
Key Terms
Annual Meeting of Stockholders, Class III directors, independent registered public accounting firm, broker non-votes, +1 more
5 terms
Annual Meeting of Stockholders financial
"the Company held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)"
Class III directors financial
"Each of Jennifer Jarrett, Anne Phillips, M.D., David Happel and George Kemble, Ph.D. were elected to the Board to serve as Class III directors"
Class III directors are members of a company’s board assigned to one of several staggered term groups, so only that class faces election in a particular year while other classes stay in place. For investors this affects corporate control and takeover risk because staggered elections make it slower and harder for an outside group to replace a majority of directors quickly—think of it as a rotating schedule for board seats that provides continuity but can also entrench existing leadership.
independent registered public accounting firm financial
"The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year was ratified"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
broker non-votes financial
"Name | | For | | Withheld | | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
emerging growth company regulatory
"Emerging growth company x"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Board change did Sagimet Biosciences (SGMT) announce in this 8-K?
Sagimet Biosciences announced that director Tim Walbert resigned from the Board effective June 12, 2026. The company states his resignation was due to other commitments and not because of any disagreement over operations, policies, or practices at Sagimet.
Which Class III directors were elected at Sagimet Biosciences’ 2026 annual meeting?
Stockholders elected Jennifer Jarrett, Anne Phillips, M.D., David Happel and George Kemble, Ph.D. as Class III directors. They will serve until the 2029 Annual Meeting of Stockholders and until their successors are elected or appointed, or earlier departure events occur.
What were the vote results for Sagimet Biosciences’ auditor ratification in 2026?
Stockholders ratified KPMG LLP as Sagimet’s independent registered public accounting firm for the 2026 fiscal year. The proposal received 19,091,619 votes for, 13,960 votes against, and 35,224 abstentions, with no broker non-votes recorded on this auditor ratification item.
How strong was support for Sagimet Biosciences director nominees at the 2026 meeting?
Support varied by nominee, with David Happel receiving 8,753,884 votes for and 262,813 withheld, and George Kemble, Ph.D. receiving 8,688,684 for and 328,013 withheld. All Class III nominees were elected, with additional broker non-votes reported for each nominee.
AI-generated analysis. How Rhea-AI works. Not financial advice.
